Facebook
Twitter
Telegram
Report an ErrorCorbus Pharmaceuticals Holdings Balance Sheet 2011-2024 | CRBP
Annual Balance Sheet Corbus Pharmaceuticals Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
263 K | -8.23 M | -66.7 M | -22.3 M | -41.4 M | -62.2 M | -14.7 M | -12.2 M | -6.12 M | 335 K | - | - | |
Long Term Debt |
- | 16 M | 15.6 M | 18 M | - | - | - | - | - | - | 331 K | - | - |
Long Term Debt Current |
1.44 M | 1.28 M | 1.14 M | 1 M | 596 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 25.1 M | 8.1 M | 1.38 M | 990 K | 70.4 K | 260 K | - | 1.44 M | - | - |
Total Current Liabilities |
31.9 M | 12.6 M | 17 M | 31.9 M | 34.9 M | 18.1 M | 8.2 M | 8.9 M | 3.63 M | 738 K | - | - | - |
Total Liabilities |
35.2 M | 33.3 M | 38.6 M | 57 M | 43 M | 19.5 M | 9.19 M | 8.97 M | 3.89 M | 738 K | 2.09 M | - | - |
Deferred Revenue |
- | - | - | - | - | 1.46 M | - | 1.94 M | 1.59 M | - | - | - | - |
Retained Earnings |
-437 M | -392 M | -350 M | -304 M | -193 M | -121 M | -65.7 M | -33.3 M | -13.3 M | -4.43 M | -1.89 M | - | - |
Total Assets |
28.3 M | 66.3 M | 108 M | 102 M | 49.1 M | 47 M | 67 M | 17.9 M | 12.9 M | 6.6 M | 306 K | - | - |
Cash and Cash Equivalents |
13.7 M | 17 M | 25 M | 85.4 M | 31.7 M | 41.7 M | 62.5 M | 15 M | 12.3 M | 6.26 M | 303 K | - | - |
Book Value |
-6.9 M | 33 M | 69.1 M | 45.3 M | 6.16 M | 27.5 M | 57.8 M | 8.92 M | 8.99 M | 5.86 M | -1.78 M | - | - |
Total Shareholders Equity |
-6.9 M | 33 M | 69.1 M | 45.3 M | 6.16 M | 27.5 M | 57.8 M | 8.92 M | 8.99 M | 5.86 M | -1.78 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet Corbus Pharmaceuticals Holdings
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 11.3 M | 14 M | 16 M | 9.39 M | 11.6 M | 13.7 M | 15.6 M | 18.6 M | 18.4 M | 18.2 M | 18 M | 18 M | 18 M | 18 M | 8.1 M | 8.1 M | 8.1 M | 8.1 M | 1.38 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
28.8 M | 35.2 M | 36 M | 34.2 M | 35.2 M | 33.3 M | 31.9 M | 32.6 M | 34.5 M | 38.6 M | 41.9 M | 43.6 M | 48.6 M | 57 M | 57 M | 57 M | 57 M | 43 M | 43 M | 43 M | 43 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M | 9.19 M | 9.19 M | 9.19 M | 9.19 M | 8.97 M | 8.97 M | 8.97 M | 8.97 M | 3.89 M | 3.89 M | 3.89 M | 3.89 M | 738 K | 738 K | 594 K | 738 K | 980 K | 980 K | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 271 K | - | - | - | 2.48 M | 27 M | 1.46 M | 1.46 M | 4.48 M | 1.46 M | - | - | 296 K | 646 K | 1.94 M | 1.94 M | 1.94 M | 1.94 M | 1.59 M | 1.59 M | 1.59 M | 1.59 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-444 M | -437 M | -429 M | -419 M | -410 M | -392 M | -381 M | -372 M | -359 M | -350 M | -339 M | -337 M | -320 M | -304 M | -304 M | -304 M | -304 M | -193 M | -193 M | -193 M | -193 M | -121 M | -121 M | -121 M | -121 M | -65.7 M | -65.7 M | -65.7 M | -65.7 M | -33.3 M | -33.3 M | -33.3 M | -33.3 M | -13.3 M | -13.3 M | -13.3 M | -13.3 M | -4.43 M | -4.43 M | -4.43 M | -4.43 M | -1.89 M | -1.89 M | - | - | - | - | - | - | - | - | - | - |
Total Assets |
126 M | 28.3 M | 36.3 M | 43.7 M | 51.6 M | 66.3 M | 73.8 M | 82.1 M | 95.7 M | 108 M | 120 M | 121 M | 140 M | 102 M | 102 M | 102 M | 102 M | 49.1 M | 49.1 M | 49.1 M | 49.1 M | 47 M | 47 M | 47 M | 47 M | 67 M | 67 M | 67 M | 67 M | 17.9 M | 17.9 M | 17.9 M | 17.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 306 K | 306 K | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
14.1 M | 13.7 M | 11.2 M | 8.35 M | 7.32 M | 17 M | 12.4 M | 25.8 M | 57 M | 25 M | 37.1 M | 36.1 M | 66.6 M | 85.4 M | 85.4 M | 85.4 M | 85.4 M | 31.7 M | 31.7 M | 31.7 M | 31.7 M | 41.7 M | 41.7 M | 41.7 M | 41.7 M | 62.5 M | 62.5 M | 62.5 M | 62.5 M | 15 M | 15 M | 15 M | 15 M | 12.3 M | 12.3 M | 12.3 M | 12.3 M | 6.26 M | 6.26 M | 6.26 M | 6.26 M | 303 K | 303 K | - | - | 542 K | - | - | - | - | - | - | - |
Book Value |
97 M | -6.9 M | 311 K | 9.52 M | 16.5 M | 33 M | 41.9 M | 49.5 M | 61.2 M | 69.1 M | 77.6 M | 77 M | 91.5 M | 45.3 M | 45.3 M | 45.3 M | 45.3 M | 6.16 M | 6.16 M | 6.16 M | 6.16 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 57.8 M | 57.8 M | 57.8 M | 57.8 M | 8.92 M | 8.92 M | 8.92 M | 8.92 M | 8.99 M | 8.99 M | 8.99 M | 8.99 M | 5.86 M | 5.86 M | 6.01 M | 5.86 M | -675 K | -675 K | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
97 M | -6.9 M | 311 K | 9.52 M | 16.5 M | 33 M | 41.9 M | 49.5 M | 61.2 M | 69.1 M | 77.6 M | 77 M | 91.5 M | 45.3 M | 45.3 M | 45.3 M | 45.3 M | 6.16 M | 6.16 M | 6.16 M | 6.16 M | 27.5 M | 27.5 M | 27.5 M | 27.5 M | 57.8 M | 57.8 M | 57.8 M | 57.8 M | 8.92 M | 8.92 M | 8.92 M | 8.92 M | 8.99 M | 8.99 M | 8.99 M | 8.99 M | 5.86 M | 5.86 M | 5.86 M | 5.86 M | -1.78 M | -1.78 M | - | - | -1.19 M | - | - | - | - | - | - | - |
All numbers in USD currency